Eterna Therapeutics Inc. (BTX)

$0.2051

+0.00 (+0.05%)
Rating:
Recommendation:
Neutral
Symbol BTX
Price $0.2051
Beta 0.787
Volume Avg. 0.09M
Market Cap 1.052M
Shares () -
52 Week Range 0.181-200.0
1y Target Est -
DCF Unlevered BTX DCF ->
DCF Levered BTX LDCF ->
ROE -240.92% Strong Sell
ROA -136.44% Strong Sell
Operating Margin -
Debt / Equity 137.44% Buy
P/E -0.07 Neutral
P/B 0.07 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BTX news


Mr. Allen Wolff
Healthcare
Biotechnology
NASDAQ Global Market

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.